You may have to Search all our reviewed books and magazines, click the sign up button below to create a free account.
Recent advances in immunology and molecular biology have resulted in new therapeutic approaches being generated and implemented in cancer clinics. The discovery of new antigens, mechanisms of antigen presentation, and interplay of cells involved in anti-tumor immunity have made the clinical control of some cancers more plausible than previously tho
Recent progress in fundamental tumor immunology has led to immunotherapy trials in patients with solid tumors and hematological malignancies. In the past, immunotherapy approaches were primarily based on enhancement of tumor immunity with cytokines and adjuvant therapy, without knowledge of relevant tumor antigens. The discovery of tumor antigens c
None
Progress in Basic and Clinical Immunology is a result of the 14th European Immunology Meeting - EFIS 2000, held in Poznan, Poland, on 23-27 September 2000. EFIS 2000 gathered over 1400 immunologists from all over the world. It was an exceptionally memorable meeting for a number of reasons: 1) it was held in the last year of the century and the millennium, thus provoking conclusions of past achievements of immunology and projections for the future; 2) it was held in Poland, a country that is a symbol of struggle for freedom for a large number of scientists originating from the `Eastern Bloc' countries; and 3) EFIS celebrated its 25th anniversary at this occasion. This comprehensive volume contains 62 chapters grouped into 11 sections: T-cells, Immune Receptors, Antigen Presentation/Dendritic Cells, Cytokines, Immunodeficiencies, Autoimmunity, Allergy/Inflammation, Immunotherapy, Vaccines, Tumor Immunology, and Cancer Immunotherapy.
The progressive growth of a malignant tumor is accompanied by a decline in the immune response, through mechanisms that have, until recently, been poorly understood. The new era of biological therapies, including cytokines, adoptive transfer of TIL cells, gene therapy and others, brought forth the need to understand the impact of the tumor on the immune system. Moreover, the inability to achieve in humans the unequivocal success of immunotherapy in murine models suggests the possibility that cancer can impair the development of a therapeutic immune response. Scientific and technological advances in cellular and molecular biology during the last two decades have provided new tools with which ...
Based on a Tumor Immunology Symposium held in Pittsburgh, this work provides comprehensive coverage of the most important aspects of tumor immunology. It reveals novel approaches to the immunotherapy of cancer and presents complex issues in an accessible manner.
Cancer Immunology is intended as an up-to-date, clinically relevant review of cancer immunology and immunotherapy. This volume focuses on the immunopathology and immunotherapy of organ cancers in detail. It clearly explains their immunology and describes novel immunotherapy for specific cancers, including pediatric solid tumors, hematologic malignancies, gastrointestinal tumors, skin cancers, bone and connective tissue tumors, central nervous system tumors, lung cancers, genitourinary tract tumors and breast cancers. In so doing, it builds on the previous two volumes in Cancer Immunology, placing basic knowledge on tumor immunology and immunotherapy into a clinical perspective with the aim of educating clinicians on advances in cancer immunology and the most recent approaches in the immunotherapy of various tumors. This translational, clinically oriented book will be of special value to clinical immunologists, hematologists and oncologists.
This book is about melanoma—its biology, immunology, and pathology, as well as the initial use of powerful genomic tools to study its fundamental mole- lar and genetic characteristics. The study of cancer will be profoundly impacted by the Human Genome Project. I would like to discuss some of these changes. The first draft of the human genome sequence was announced in June 2000, and we have just scratched the surface of the changes it will engender in medicine. A relevant question is what are the long-term effects of the Human Genome Project for medicine? I would argue that there are three, and each of these three point toward the view that systems biology will dominate biology and medicin...
This comprehensive volume explores the latest research on the mechanisms of resistance in cancer cells to CTL-mediated immunotherapy. Chapter topics discuss cell-mediated immunity as the result of cytotoxic T-lymphocytes (CTL) directed specifically against cancer cells. In addition, the volume reviews how CTL mediate the cytotoxic activity, in large part, by the indication of apoptosis; hence, tumor cells develop anti-apoptotic mechanisms and thereby, resist CTL-induced apoptosis. In order for CTL-mediated antitumor immunotherapy to be effective, it is essential that agents directed against the resistant tumor cells sensitized cancer cells for CTL-mediated apoptosis. Examples of such agents discussed in the volume include are HDAC inhibitors, proteasome inhibitors, Bcl-2 family inhibitors, PARP, antibodies, and more.